Clinical Trials
Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials
AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside...
News
Gilead Sciences signs joint procurement agreement with the European Commission for Veklury (remdesivir)
Gilead Sciences and the EC signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir), the first antiviral...
News
Regeneron’s REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients
Regeneron Pharmaceuticals, Inc. announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing...
Press Releases
Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
Roche announced that it intends to launch a high-volume SARS-CoV-2 Antigen test as an aid in the diagnosis of Severe Acute Respiratory Syndrome Coronavirus...
News
BryoLogyx Announces Completion of World’s First GMP Synthesis of Bryostatin-1
BryoLogyx, Inc., announced that it has completed the synthesis of bryostatin-1 molecule, pursuant to FDA’s Good Manufacturing Practice (GMP) regulations. Bryostatin-1 is the company’s...
Drug Research
FUJIFILM Diosynth Biotechnologies Stands Ready to Manufacture Lilly COVID-19 Antibody for Low- and Middle-Income Countries
FUJIFILM Diosynth Biotechnologies, a world leading Contract Development and Manufacturing Organization (CDMO) for biologics, viral vaccines and viral vectors, announced that it will manufacture...
Press Releases
Thermo Fisher Scientific Further Expands COVID-19 Test Portfolio with Two New Antibody Tests
Thermo Fisher Scientific Inc., the world leader in serving science, introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19 Total Antibody ELISA...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read